Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] LIG D&A (079550) – Shinhan Securities | 4Q25 One-off Shock · KRW 26.2T Backlog · Long-term Structural Growth / 2026-02-20 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] Alteogen (196170) – Hana Securities | GSK Single-Asset Deal Analysis · Expanding SC Competitiveness · Ongoing 2026 Deal Catalysts / 2026-01-21 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Failure · Grabody Platforms · Intrinsic Value / 2026-04-28 Research
  • [IR] Samsung Electronics (005930) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room

[Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26

Posted on June 26, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Hana Securities

Analyst : Rokho Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 3,600,000 (Upgraded)

Core Momentum : Stronger commodity DRAM pricing in the second half and an improving HBM4-led product mix are expected to drive further earnings upgrades, while long-term supply agreements and the ADR listing support higher earnings visibility and premium valuation multiples.

📊 1. [Valuation & Key Financial Metrics]

  • KOSPI Index (pt): 8,930.30
  • 52-Week High / Low (KRW): 2,919,000 / 245,000
  • Market Capitalization (KRW bn): 2,078,952.8 (Market Cap Weight (%): 28.44)
  • Shares Outstanding (k shares): 730,492.4 / Foreign Ownership (%): 50.78
  • 60-Day Average Trading Volume (k shares): 5,226.0 / 60-Day Average Trading Value (KRW bn): 9,419.4
  • Major Shareholder Stakes (%): SK Square and 8 others 20.50, National Pension Service 7.50
  • 2026F Estimates: Revenue KRW 374,597.3 bn, Operating Profit KRW 265,768.3 bn, Net Income KRW 220,863.8 bn, EPS KRW 305,329, BPS KRW 478,839
  • 2027F Estimates: Revenue KRW 543,330.5 bn, Operating Profit KRW 385,285.3 bn, Net Income KRW 309,027.0 bn, EPS KRW 422,175, BPS KRW 899,929

🚀 2. [Market Opportunities & Business Outlook]

  • SK hynix’s 2Q26 revenue is projected at KRW 87.1 trillion (YoY +292%, QoQ +66%) and operating profit at KRW 67.6 trillion (YoY +638%, QoQ +80%), maintaining memory price assumptions with minor upward FX adjustments, delivering high profitability driven by product mixes focused on HBM, high-end DRAM, and eSSD.
  • Operating profit forecasts for 2026 and 2027 have been revised upward by 8% and 18%, respectively, as general DRAM prices in 2H26 are expected to exceed current baseline assumptions led by LPDDR.
  • Amid ongoing 2027 HBM price negotiations, blending ASP increases as HBM4 emerges as a core product and new pricing structures are established are expected to contribute to further 2027 earnings upgrades.
  • The ADR listing schedule has been finalized, and details regarding long-term supply agreements were identified through Micron’s earnings release, suggesting that premium valuation multiples are justified given the high earnings visibility tied to long-term supply agreements.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as a high-value memory enterprise whose earnings power is further solidified by general DRAM price recovery in the second half and product mix enhancements centered on HBM4. This perspective places major emphasis on justifying premium multiple expansions backed by high earnings visibility derived from ADR listings and long-term supply agreements, extending beyond near-term earnings beats.

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking whether second-half general DRAM price hikes driven by LPDDR translate into actual earnings improvements, and observing the realization of blended ASP growth and HBM4 adoption during 2027 HBM price negotiations. In addition, it is necessary to verify whether the progression of the ADR listing schedule and high visibility from long-term supply agreements materialize into sustained multiple expansion. These developments can be tracked through quarterly and annual earnings releases, official corporate IR materials, and regulatory filings on DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Samsung SDI (006400) – Mirae Asset Securities | Data Center ESS · Potential SDC Monetization · Operating Profit Turnaround / 2026-06-26
Next Post: [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 Ramp-up · Resolution of Labor Risk · Annual Guidance Delivery / 2026-06-29

Related Posts

  • [Research] Samsung SDI (006400) – Hana Securities | Turnaround to Profit · North America ESS Ramp-Up · Valuation Upside / 2026-07-31 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28 Research
  • [Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Server Demand · Supply Deficit · FCBGA Technical Bottleneck / 2026-07-20 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | Sanofi Strategy · Grabody B Validity · Muscle Shuttle Expansion / 2026-02-02 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Turnaround to Profit · North America ESS Ramp-Up · Valuation Upside / 2026-07-31 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Record 3 Out-Licensing Deals in 2026 · Rapid Keytruda SC Rollout · H2 Clinical Pipeline Catalysts / 2026-08-06 Research
  • [IR] SK hynix (000660 / SKHY) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Infrastructure · LTA · HBM Demand / 2026-06-09 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Stepwise Loss Reduction · Strong ESS BBU Shipments · 4Q26 Turnaround / 2026-02-03 Research
  • [Research] Samsung SDI (006400) – Hana Securities | SDC Stake Monetization Pursuit · Up to KRW 11T Liquidity · Valuation Multiples Re-rating / 2026-02-20 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Server CPU Demand · HBM Diversification · HBM4 / 2026-05-07 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme